Clinical trial
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
NCT06662539
Study timeline
Study start (actual)2024-12-09Date precision: day
Registry last updated2026-03-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Obesityunresolved
Interventions
PetrelintideDRUG
PlaceboDRUG
Sponsors & collaborators
Zealand Pharmalead sponsor
Parexelcollaborator
Mapped research locations
BucharestRomania4ChicagoIllinois, United States1MiamiFlorida, United States1San AntonioTexas, United States1BirminghamAlabama, United States1CharlotteNorth Carolina, United States1The BronxNew York, United States1LexingtonKentucky, United States1WichitaKansas, United States1KnoxvilleTennessee, United States1West Palm BeachFlorida, United States1ClearwaterFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06662539 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.